A Phase 3 interventional study of Somatropin (rDNA origin) for injection in Failure to Thrive, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2010-12-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Failure to Thrive with a site in United States — 4 open to participants now, 7 under way, 2 of them phase 3. Failure to Thrive · United States.
Among the 30 studies in Failure to Thrive with a site in United States, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2000, is one of 7 in phase 3, and was the 2nd registered.
84 studies on the registry are indexed under Failure to Thrive; 12 are open to participants now.
Browse Failure to Thrive studies →4 of the 30 studies in Failure to Thrive with a site in United States are open now. Recruiting first, the newest first:
Ascendis Pharma A/S · Sites in United States, France, Germany and 4 more countries
Ages 2–17
Northwell Health · Sites in United States
Ages 5–15 · Healthy volunteers
Ascendis Pharma Endocrinology Division A/S · Sites in United States
Ages 1–18
Columbia University · Sites in United States
Ages 1 days–21 days
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Failure to Thrive studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 1
First in 1989; this study’s year is marked. 1 started in 2000.
This study's enrollment of 75 is below the median of 100 across 56 interventional studies indexed under Failure to Thrive.
Median enrollment 75 across the 23 interventional studies, 247 across the 6 observational. Of the 21 that completed or were terminated, 7 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 30 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 1 study filed under Failure to Thrive — fewer than ten, so there is no comparison to draw.
2 of the studies in Failure to Thrive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04294368Columbia UniversityTargeted Fortification of Donor Breast Milk in Preterm Infants | 2027-03 |
| NCT03717584University of California, DavisA Cohort Study of the Intestinal Microbiota of Premature Infants | 2027-03-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Failure to Thrive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls with Turner syndrome. After the second year patients in the control group have the option to receive treatment as well. All patients will optionally be treated until they achieved adult height.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Comparison of first year height velocity of somatropin-treated versus non-treated patients with SHOX deficiency.
Comparison of second year height velocity of somatropin-treated versus non-treated patients with SHOX deficiency.
Non inferiority to somatropin treated patients with Turner syndrome
Adult height of treated patients
The record gives a start of Feb 2000, a primary completion of Jul 2004 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone